CNBX Pharmaceuticals Inc CNBX
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.02
- Shares Outstanding
- 1.61B
- Market Cap
- $245,153.62
- Volume/Avg
- 30M / 11M
Key Statistics
- Price/Earnings (Normalized)
- 0.20
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
- Website
- https://www.cnbxpharma.com
Valuation
|
Metric
|
CNBX
|
|---|---|
Price/Earnings (Normalized) | 0.20 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CNBX
Financial Strength
|
Metric
|
CNBX
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | −14.13 |
Quick Ratio
CNBX
Profitability
|
Metric
|
CNBX
|
|---|---|
Return on Assets (Normalized) | −3,043.76% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CNBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^>#pQl | LOCK|rn^m@ | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!dF<?&% | LOCK|TcH%y | $76B | |||
| Moderna Inc
MRNA
| LOCK|#@&T%^ | LOCK|x> | $75B | |||
| argenx SE ADR
ARGX
| LOCK|!y@!pW | LOCK|%@G | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|G&W@X&D | LOCK|NG | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|xb>B?!j | LOCK|J$T? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nJpgrfqn | LOCK|tW%rm | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|pn#!#! | LOCK|Vt | $24B | |||
| Incyte Corp
INCY
| LOCK|m&rb@JR | LOCK|&tb | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|sQ#s^w^ | LOCK|?D | $15B |
United States